

PATIENT NAME	Report, Sample	ACCESSION	25052200001
PATIENT DOB	Jan. 1, 2025	ORDER CODE	GX25-0000665
PATIENT GENDER	U	SAMPLE TYPE, SOURCE & COLLECTION DATE	
PATIENT PHONE	(919) 313-9672	Serum	05-20-2025, 09:12AM (EDT)
ACCOUNT	Mosaic Diagnostics	Urine	05-20-2025, 09:12AM (EDT)
PROVIDER	Test Provider	RECEIVED	05-22-2025, 09:12AM (EDT)
REPORT STATUS	FINAL	REPORTED	05-22-2025, 09:13AM (EDT)
TEST INFORMATION	4. Dual Detect: Lyme Borrelia Direct Detect - Nanotrap® + Bartonella IgG Detect - IFA	DIAGNOSIS CODES	

QUALITATIVE RESULTS		
	RESULT	FLAG
4-SPECIES IFA SEROLOGY PANEL, IGG		
Bartonella henselae IFA Serology, IgG	1:64	REACTIVE
Bartonella koehlerae IFA Serology, IgG	≥1:256	REACTIVE
Bartonella quintana IFA Serology, IgG	1:128	REACTIVE
Bartonella vinsonii berkhoffi IFA Serology, IgG	1:256	REACTIVE
BORRELIA URINE TEST		
Lyme Borrelia Nanotrap®	DETECTED	DETECTED

4-Species IFA Serology Panel, IgG: Test Result Interpretation

Reactive: A Bartonella species titer greater than or equal to 1:64 indicates the tested serum sample was reactive to the indicated Bartonella species antigen(s), and that the patient has been exposed to, or may presently be infected with, a Bartonella species.

Non-Reactive: IFA results with a Bartonella species titer of less than or equal to 1:32 indicates the tested serum sample was non-reactive with the indicated Bartonella species antigen(s).

Indeterminate: Unable to determine definitive reactivity status. Submission of an additional sample for repeat testing is recommended.

The expected ("Reference") value in the normal population is "Non-reactive" to Bartonella henselae, Bartonella quintana, Bartonella koehlerae, or Bartonella vinsonii berkhoffii. Serological results should be interpreted in the context of patient history, possible past exposure, other clinical findings, and laboratory results.

Research studies have shown that some bacteremic patients do not develop antibodies.

Lyme Borrelia Nanotrap®: Test Result Interpretation

Not Detected (Nanotrap®) - Lyme Borrelia OspA antigen was not detected in the patient's urine.

Detected (Nanotrap®) - Lyme Borrelia spp. OspA antigen was detected in the patient's urine. The patient should consult with their physician to review test results and discuss treatment options.

Lack of detection by the Lyme Borreliosis Nanotrap® Urine Test of target OspA antigen may be due to variable species-specific limits of detection.

Failure to detect infection with a Lyme Borrelia spp. using the Nanotrap® Urine Test does not rule out a diagnosis of Lyme borreliosis, as laboratory tests are only one component utilized by physicians to diagnose and treat potential infections. The patient should consult with their physician to discuss test results and other options.

The expected ("Reference") value in the normal population is target organism genus/species "Not Detected".



Mosaic Diagnostics
CLIA ID: 17D0919496
Laboratory Director: Dr. Sean Agger PhD, MS, MBA, DABCC, DABMM

9221 QUIVIRA RD
OVERLAND PARK, KS 66215
P: (800) 288-0383 F: (919) 341-6207

PATIENT NAME	Report, Sample	ACCESSION	25052200001
PATIENT DOB	Jan. 1, 2025	ORDER CODE	GX25-0000665
PATIENT GENDER	U	SAMPLE TYPE, SOURCE & COLLECTION DATE	
PATIENT PHONE	(919) 313-9672	Serum	05-20-2025, 09:12AM (EDT)
ACCOUNT	Mosaic Diagnostics	Urine	05-20-2025, 09:12AM (EDT)
PROVIDER	Test Provider	RECEIVED	05-22-2025, 09:12AM (EDT)
REPORT STATUS	FINAL	REPORTED	05-22-2025, 09:13AM (EDT)
TEST INFORMATION	4. Dual Detect: Lyme Borrelia Direct Detect - Nanotrap® + Bartonella IgG Detect - IFA	DIAGNOSIS CODES	

Tests included in this report were performed and analyzed at Galaxy Diagnostics. Reference laboratory test results may not be altered. These tests were developed and their performance characteristics determined by Galaxy Diagnostics. These tests have not been cleared or approved by the FDA. Galaxy Diagnostics (CLIA ID 34D2027997, Laboratory Director: Susan Orton, PhD, D(ABMLI)) is located at 6 Davis Drive. Suite 201, Research Triangle Park, NC.